Startup Raises $3.2M for EHR App for Google Glass

San Francisco-based Augmedix, a health IT startup that has developed an app that records to and then displays patients’ records through Google Glass, has raised $3.2 million in venture capital to grow the company and increase outreach efforts.

Advertisement

The app is designed to foster eye contact and better communication during physician-patient interactions. While wearing Google Glass with the app during a patient visit, a physician is able to record information gathered during the visit into the patient’s records, and then call up the record or other relevant resource later using voice commands, according to a report in the San Francisco Chronicle.

“Doctors spend more than one third of their day on the computer, inputting or retrieving data from electronic health records. The amount of data and documentation is overwhelming,” said Augmedix CEO Ian Shakil in a news release. “Powered by Google Glass, Augmedix rehumanizes the doctor-patient interaction by delivering patient satisfaction, doctor efficiency, doctor satisfaction and health record quality.”

More Articles on Google Glass:

5 Hospitals Using, Piloting Google Glass
Bridging the Physician Shortage With Google Glass
5 Health IT Startups to Watch

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

What clinicians need from AI after the pilot: Lessons from Adventist Health and Rady Children’s

Friday, July 24
12:00 PM - 1:00 PM CDT

Presenters: Dr. Dieter Sumerauer, Rady Children’s HealthDr. Salman Naqvi, AdventistDr. Reid Conant, Abridge

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.